Browsing by Author "Shoge, Ruth"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Feasibility of monitoring compliance with intermittent occlusion therapy glasses for amblyopia treatment
    (Elsevier, 2019) Wang, Jingyun; Jin, Jing; Malik, Ayesha; Shoge, Ruth; Meiyeppen, Siva; Pang, Yi; Yin, Kelly; Allen, Megan; Scombordi, Brandy; Soni, Ajay; Neely, Daniel E.; Januschowski, Kai; Ophthalmology, School of Medicine
    Background Liquid crystal glasses use an intermittent occlusion technique and may improve compliance compared to adhesive patches. Previous studies support the effectiveness of intermittent occlusion therapy (IO therapy) glasses for amblyopia treatment. However, objective compliance for these glasses has not been measured. The purpose of this study was to investigate the feasibility of using a microsensor to monitor objective compliance with IO therapy glasses. Methods Children 3 to ≤8 years of age with unilateral amblyopia were enrolled. All subjects had optimal refractive correction (if needed) for at least 5 weeks without improvement. Subjects were prescribed IO therapy glasses, set at 30-second opaque/transparent intervals (ie, occluded 50% of wear time). Wear time was prescribed according to amblyopia severity. For each patient, objective compliance with the IO therapy glasses was monitored by means of a microsensor. Results A total of 13 subjects returned with microsensor data. Compliance varied among and within individuals. General compliance averaged 51.6% (range, 10%-97%). Mean daily compliance decreased slightly over time. On average, patients’ visual acuity improved 0.14 ± 0.15 logMAR (range, −0.1 to 0.5 logMAR). No parents reported that their child had social concerns related to the attached microsensor. Conclusions Objective compliance with IO therapy glasses can be monitored by a simple microsensor reliably. In our study cohort, objective compliance with IO therapy glasses varied among individuals, but on average it declined slightly over time.
  • Thumbnail Image
    Item
    Intense versus standard regimens of intermittent occlusion therapy for unilateral moderate amblyopia in children: study protocol for a randomized controlled trial
    (BMC, 2020-04-28) Wang, Jingyun; Malik, Ayesha; Jin, Jing; Pang, Yi; Yin, Kelly; Allen, Megan; Grigorian, Adriana; Scombordi, Brandy; Bailey, Joann; Aljohani, Saeed; Funari, Katharine; Shoge, Ruth; Meiyeppen, Siva; Myung, Jenny; Soni, Ajay; Neely, Daniel E.; Ophthalmology, School of Medicine
    Background: We reported that in our previous study that wearing intermittent occlusion therapy glasses (IO-therapy) for 4 hours (h) was non-inferior to patching for 2 h in 3 to 8-year-old children with amblyopia. We hypothesize that an intense regimen of 12-h IO-therapy per day for 4 weeks could be as effective as the standard regimen of 4-h IO-therapy per day for 12 weeks in treating moderate amblyopia in 3 to 8-year-old children. Methods/design: A total of 56 children between 3 and 8 years of age with amblyopia in association with anisometropia and/or strabismus will be enrolled. All participants will be prescribed IO-therapy glasses (Amblyz™), set at 30-s opaque/transparent intervals (i.e., occluded 50% of wear time). They will be randomized to receive the standard regimen for 12 weeks or the intense regimen for 4 weeks. Adherence to using the IO-therapy glasses will be objectively monitored in each participant by means of a microsensor dose monitor. The primary study objective is to compare the effectiveness of an intense regimen to a standard regimen of IO-therapy in 3 to 8-year-old children with moderate amblyopia. The secondary study objectives are to determine whether adherence differs between an intense regimen and a standard regimen of IO-therapy, and to determine the dose-response relationship of IO-therapy. Discussion: In addition to testing the effectiveness, this study will test for the first time the association between treatment adherence and the visual outcome of IO-therapy, which will enhance our understanding of the dose-response relationship of IO-therapy. If an intense regimen is shown to be effective, it would alter amblyopia treatment strategies and improve visual outcomes. Trial registration: ClinicalTrials.gov: NCT02767856. Registered on 10 May 2016.